Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 22, 2007

Lux Biosciences Broadens Biomaterials Technology Deal with Rutgers

  • Lux Biosciences expanded its existing technology licensing agreement with Rutgers, The State University of New Jersey. The new deal adds exclusive rights to some of the University's polycarbonate intellectual property estate for ophthalmic use after the September 2006 pact gave Lux Biosciences access to the polyarylate patent portfolio.

    "These second-generation polycarbonates are a valuable addition to the Lux Biosciences portfolio of licensed Rutgers technologies that gives us further flexibility in choosing the best possible technology and tailoring it to the molecule at hand," remarks Ulrich Grau, Ph.D., president and CEO.

    The license includes several issued patents that specifically disclose methods of generating drug-release formulations for peptides using polymers as the drug delivery matrix. The platform gives Lux Biosciences access to a broader range of polymers that are all bioerodible and based on similar monomeric building blocks. The company believes it will provide a variety of features for the controlled long-term delivery of medications to the eye.

    "Second-generation polycarbonates are among the most advanced biomaterials currently available," states board of governors professor Joachim Kohn who led the team of Rutgers researchers and students who invented this technology. “I am convinced that this class of biomaterials will find significant medical applications in drug delivery, medical devices, and regenerative medicine.”


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »